BioStem Technologies, Inc. (BSEM)
BioStem Technologies, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Fort Lauderdale, FL, US. The stock last traded at $3.87, up 7.20% on the session, giving a market capitalisation of $65.7M. On trailing twelve-month figures it carries a trailing P/E of -3.28, a net margin of 105.1%. Its beta of 0.26 implies it has historically moved less than the broad market.
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
BioStem Technologies, Inc. is most often compared with the following Healthcare names: